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previous cigar use (OR 3.44model 1, OR 2.05model 2, OR 2.67model 3), previous
alcohol use (OR 2.1 model 1), having friends (OR 3.87model 1, OR 2.74model 2)
and/or siblings (OR  3.18 model 1, OR  2.53 model 2, OR  2.86 model 3) that use
waterpipes, were significant predictors of waterpipe smoking. Perception of harm
equivalent to cigarettes ormorewas associatedwith less use (OROR 0.262model
2, OR  0.305 model 3). CONCLUSIONS: High rates of waterpipe smoking in both
gendersweredocumented, evenamongparticipants recognizing theassociatedharm.
Data suggests the importance of incorporating the predictors identified in future in-
tervention strategies.
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OBJECTIVES: To assess the association between use of inhaled tobramycin andmor-
tality in patientswith cystic fibrosis and chronic Pseudomonas aeruginosa (PA) infection.
METHODS: Patients aged 6 years with FEV1 %-predicted 25-75% and chronic PA
infection were identified from the United States Cystic Fibrosis Foundation’s Patient
Registry (1996 –2008). Patients were followed from the first year in which all these
criteria weremet (index year) to death or end of continuous data availability. Longitu-
dinal logistic regression was used to assess the association between current-year re-
porteduseof inhaled tobramycin and subsequent-yearmortality,with adjustment for
demographics, comorbidities, reported use of dornase alpha or high-dose ibuprofen,
FEV1 %-predicted and medical resource use. RESULTS: Among 12,740 patients meet-
ing inclusion criteria, 2,538 deaths were observed during a median follow-up of 6
years. At index, mean age was 22 years, mean FEV1 %-predicted was 62%, 16% were
underweight for age and 64% reported inhaled tobramycin use. After regression ad-
justment, use of tobramycin inhalation solutionwas associatedwith a significant 21%
reduction in the odds of subsequent yearmortality (odds ratio: 0.79, P 0.001). Use of
dornase alfa was similarly associated with reduced mortality (odds ratio: 0.85, P 
0.005). In the same regression model, underweight for age, cystic fibrosis-related dia-
betes, female gender,worse lung function and cultures positive for PAor Burkholderia
cepacia complex, amongmultiple other patient characteristics, were associated with
significantly increased mortality. Adjusted mortality rates for patients reporting to-
bramycin inhalationsolutionuse inall vs.noneof the follow-upyearswere1.3vs. 2.1%
at 2 years, 5.2 vs. 8.0% at 5 years and 9.9 vs. 15.0% at 10 years. CONCLUSIONS: After
adjusting for clinical status and other treatments, inhaled tobramycin use was asso-
ciated with significantly reduced mortality among cystic fibrosis patients meeting
recommended criteria for inhaled tobramycin use.
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OBJECTIVES: Cystic fibrosis (CF) is the most common fatal genetic disease in Cau-
casians with an annual birth incidence of 1:2,500. CF is ultimately fatal due to
progressive dysfunction of organs such as lung and pancreas. Improved knowledge
of the ion channel defect that causes the disease has raised the possibility of
treating the cause of CF. To develop an understanding of how different factors
contribute to disease progression, published evidencewas used to develop amodel
of mortality as a function of age and prognostic factors. METHODS: A systematic
literature review of CF disease progression was performed in Medline and Embase.
Prospective and retrospective cohort studies as well as case-control studies were
included if they reported mortality jointly with prognostic factors. Covariates of
interest included gender, lung function, weight-for-age, pancreatic sufficiency, di-
abetes, lung microflora and number of acute exacerbations. Results were synthe-
sized by means of Bayesian meta-analysis techniques. RESULTS: Seven studies
provided data on over 22,000 patients, which helped to develop a survival model
based on age and the prognostic factors. Survival over time was described with a
Gompertz model with its scale parameter affected by birth cohort, gender, lung
function, infection with Burkholderia cepacia and Staphylococcus aureus, diabetes,
number of exacerbations, and pancreatic sufficiency. The shape parameter was
assumed to be only affected by birth cohort. CONCLUSIONS: A survival model was
developed that estimates remaining life expectancy for CF patients based on their
clinical characteristics. Lung function is the primary determinant of life expec-
tancy, but several other factors have major impact. Of these, lung function and
acute exacerbations are direct targets of intervention, while infections may be
prevented or treated, and diabetes and pancreatic insufficiency may be methodi-
cally managed to potentially improve survivorship.
Respiratory-Related Disorders – Cost Studies
PRS9
COMPARISON OF THE BURDEN AND COST DRIVERS OF COPD
HOSPITALIZATION BETWEEN HISPANIC AND WHITE POPULATION IN THE
UNITED STATES
Borrego M1, Roberts M2, Petersen H3, Kharat AA1, Blanchette C4
1University of New Mexico, Albuquerque, NM, USA, 2University of New Mexico College of
Pharmacy, Albuquerque, NM, USA, 3Center for Pharmacoeconomic and Outcomes Research,
Albuquerque, NM, USA, 4Lovelace Respiratory Research Institute, Davidson, NC, USA
OBJECTIVES: The purpose of the study is to compare the costs, cost drivers and
prevalence of COPD-related hospitalizations for Hispanic andWhite patients in US
hospitals. METHODS: A retrospective cohort of COPD related hospitalized patient
discharges in 2007 were identified from a nationally representative database of
over 500 hospitals. Subjects were included if they had primary diagnosis code for
COPD (ICD9-CM 491, 492 or 496), Hispanic or White race and of age 18. COPD
related discharge rates for US population were calculated using hospital discharge
data and projection weight methodology and were further stratified by race. His-
panic discharges were matched (1:3) to comparison group of White discharges by
sex, severity score, and 5-year age ranges for an analysis of mortality and mean
costs. Unadjustedmortality andmean costs were compared by race, and cost driv-
ers were identified using a gamma generalized linear model incorporating gener-
alized estimating equations to account for the non-independent matched
discharges. RESULTS: The calculated national estimates for COPD related dis-
charges were: 490,636 total discharges including 71.4%White and 2.6% (n 12,661)
Hispanic. The study population was comprised of a cohort of 1,644 Hispanic dis-
charges meeting the inclusion criteria and a matched group of 4,932 White dis-
charges. For matched discharges the mortality rate for Whites was significantly
higher than Hispanics (1.4% White vs. 0.23% Hispanic, p.006). Hispanics had sig-
nificantly higher (P.01) unadjustedmean total patient costs ($7,356) versuswhites
($6,748), with no difference in length of stay. Hispanic hospitalizations had signif-
icantly higher costs than White hospitalizations (P  .0001). Regression analysis
identified the significant cost drivers: severity score, Hispanic race, LOS, ICU days,
urban hospital, and teaching hospital, (all with P  .025). CONCLUSIONS: As the
Hispanic population and COPD prevalence continue to rise; differences in burden,
cost, cost-drivers and treatment patterns in Hispanics warrant additional investi-
gation in an attempt to target services and reduce the burden.
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OBJECTIVES: In Nicaragua, 30% of current morbidities are associated with tobacco
smoking. Tobacco control policy measures have been initiated in this Central Ameri-
can country, however thepopulationdoesn’t have full consciousness of the long-term
consequences of tobaccouse. The aimof this studywas to compare thedirectmedical
costs of smoking cessation therapies with varenicline, nicotine replacement therapy
(NRT) and unaided cessation in Nicaragua over two time-horizons: 10 and 20 years.
METHODS: The current annual costs of chronic obstructive pulmonary disease
(COPD), lungcancer, coronaryheartdisease (CHD)andstrokewereestimatedbasedon
the current annual incidence for each disease using one public hospital databases
(Hospital Lenin Fonseca, 2010). The Benefits of Smoking Cessation on Outcomes (BE-
NESCO) simulationmodel was used to obtain the projected direct costs for each strat-
egy. An adult cohort (n3,639,948) fromNicaraguawas used and the assessment was
conducted using the healthcare payer’s perspective. Costs were discounted at 3% an-
nually. Probabilistic sensitivity analyses were conducted using Monte Carlo second
order approach. RESULTS: Varenicline is associatedwith the highest healthcare cost-
savings compared with the other two alternatives at 10 and 20 years. Results at 10
years, showed that varenicline would save US$126,599 and US$188,582 against NRT
and unaided cessation, respectively. In 20 years, savings would be US$3,609,463 and
US$5,971,233 against NRT and unaided cessation. The results of probabilistic sensitiv-
ity analyses support these findings. CONCLUSIONS: The use of a smoking cessation
therapy with varenicline would generate savings in the long-term in almost 6million
dollars to Nicaragua’s healthcare institutions.
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OBJECTIVES: To estimate the direct medical costs and indirect costs of food-in-
duced allergic reactions and anaphylaxis in the U.S. METHODS: Costs were esti-
mated with a bottom-up approach from a societal perspective: the average cost of
illness per patientwas calculated andmultiplied by reported prevalence estimates.
Patients with an inpatient admission, emergency department admission, office-
based physician visit, or outpatient visit for a food-induced allergic reaction were
identified from a list of federally administered 2006 and 2007 databases by using
ICD-9 codes. Indirect costs were quantified by estimating the lost productivity, in
terms of lost earnings due to absenteeism and mortality, of patients or caregivers.
Sensitivity analyses were conducted to measure the robustness of the estimates.
RESULTS: For 2007, direct medical costs were $225 million and indirect costs were
$115million. Office visits accounted for 52.5% of costs, and the remainder was split
between emergency visits (20%), inpatient hospitalizations (11.8%), outpatient vis-
its (3.9%), ambulance runs (3%), and epinephrine devices (8.7%). Simulations from
probabilistic sensitivity analyses suggested mean direct medical costs were $307
million and indirect costswere $203million.CONCLUSIONS:The economic burden
of allergic reactions due to food and anaphylaxis was an estimated half a billion
dollars in 2007. Ambulatory visits accounted for more than one half of costs.
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OBJECTIVES: Chronic obstructive pulmonary disease(COPD) is a highly prevalent dis-
ease and the sixth cause of death in Korea. This study examined the national epide-
miology and economic impact of COPD in Korea. METHODS: This study used the
societal cost of illness framework, consisting of epidemiology of COPD, directmedical
costs,directnon-medical costs, and indirect costs.National-levelhealthsurvey results
and insurance claim databases were used to analyze annual healthcare utilization,
hospitalization costs and outpatient costs of the total Korean population (48 million
people). Using a data mining technique, we identified medical claims with interna-
tional classification of disease 10 codes for COPD and estimated the costs by amacro-
costingmethod.RESULTS: The prevalence rate of COPDbased on theGlobal Initiative
for chronic obstructive lung disease(GOLD) criteria was estimated at 13.1% and its
mortality rate was 14.9 persons per 1,000 population in 2008. According to the classi-
fication of the GOLD, for the population over 45 years, the stage 1 group accounted for
the largest proportion(55.2%), followed by the stage 2(37.2%), stage 3(6.4%), and stage
4(1.2%). The total societal cost of COPD in 2009 was estimated at $266.4 million for
700,812 patients. The directmedical cost for COPDwas $148.7million, which includes
hospitalization cost of $72.8 million and outpatient cost of $75.9 million. The direct
non-medical cost, involving transportation cost and caregiver cost, was estimated at
$20.4 million. Indirect costs associated with morbidity and mortality of COPD were
$97.3 million. CONCLUSIONS: The study showed that the COPD had a great effect on
healthcare costs, particularly thedirectmedical cost. Therefore, appropriate interven-
tion that result inpatientswithCOPDspending less time in thehospital are likely to be
cost effective and long-term regular management is also necessary to lower the eco-
nomic burden of COPD in Korea.
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OBJECTIVES: To develop a model which calculates economic consequences of
treatment of cattle at high risk of developing Bovine Respiratory Disease (BRD
high-risk cattle), themost common and economically detrimental cattle disease in
US feedlots. Themodel had to be easily adaptable to clinical variations and regional
and timely changes in cost data. METHODS: A decision tree was developed in MS
Excel evaluating the consequences of initial treatment of BRD high-risk cattle with
tulathromycin, florfenicol, and tilmicosin on total costs and losses associated with
BRD and its treatments over an entire feeding period. Clinical data were derived
from 5 comparative trials considering success rate of initial treatment of BRD high-
risk cattle, occurrence and outcome of subsequent BRD outbreaks, chronic cases,
andmortalities. Themodel allows the estimation of results separately according to
outcomes of one of the 5 clinical trials. Cost parameters included cattle purchase,
treatment costs (first and re-treatments), costs of chronic and dead cows (perspec-
tive of the producer). RESULTS: Considering cost data derived from multiple
sources as of 2010, total costs over the entire feeding period associated with first
and subsequent BRD treatments were lowest with tulathromycin, regardless of the
study selected as basis for efficacy data. Total treatment costs for one cattle ranged
from $27.78 to $54.38 (tulathromycin), $52.83 to $84.06 (florfenicol), and $41.35 to
$141.13 (tilmicosin), and cost savings with tulathromycin were calculated between
$19.65 and $43.59 (vs. florfenicol) and $9.77 and $86.75 (vs. tilmicosin), depending
on the clinical trial considered as basis for efficacy data. Savings with tulathromy-
cin were attributed to fewer BRD treatments, less chronics and mortalities.
CONCLUSIONS: Themodel allows the estimation of total costs of treatment of BRD
high-risk cattle considering various clinical outcomes as reported in 5 trials, being
easily adaptable to high variability of cost and income data in livestock.
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OBJECTIVES: Chronic Obstructive Pulmonary Disease (COPD) is a rising concern in
high population areas, such as Mexico City, where the prevalence is estimated at
around 8%. The objective of this study was to examine if the recently available
treatment for COPD, indacaterol, was more cost-effective than the therapeutic
alternatives already available. METHODS: A cost-effectiveness analysis was per-
formed from an institutional perspective (Mexican Institute of Social Security,
IMSS). The comparators used were salmeterol and tiotropium, both alternatives
available within the National Formulary and recommended by the National Treat-
ment Guidelines for COPD. Effectiveness data was taken from published literature;
the effectiveness parameter usedwas Forced Expiratory Volume in 1 second (FEV1);
dosage regimens compared were indacaterol 300 g vs. tiotropium 18 g, and in-
dacaterol 150 g vs. salmeterol 50 g. Resource use data was obtained from the
institution; total direct costs of physician consults, lab and image tests, hospital-
ization and emergency room visits, and treatments were considered. The source of
the unit costs was the institution, current for 2010. All costs are expressed in local
currency (Mexican Pesos, MXP). The time horizon was less than 1 year; no discount
rate was used. The analytical tool used to build the model was a decision tree. A
probabilistic sensitivity analysis was performed through a Monte Carlo simulation
with 100,000 iterations to confirm the robustness of the model. RESULTS: The
results show a cost-effectiveness ratio of $13 MXP per mL of FEV1 increased for
indacaterol, compared to $13.7 MXP for tiotropium. Likewise, a cost-effectiveness
ratio of $12.9 MXP permL of FEV1 increased for indacaterol, compared to $14.3 MXP
for salmeterol, confirmed that indacaterol is a more cost-effective alternative
(dominant) for the treatment of COPD. CONCLUSIONS: From an institutional per-
spective inMexico, indacaterol is amore cost-effective (dominant) alternative than
either tiotropium or salmeterol for the treatment of COPD.
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OBJECTIVES: To evaluate the cost-effectiveness of fluticasone furoate vs. mome-
tasone furoate in the treatment of ocular symptoms in allergic rhinitis patients in
Mexico.METHODS: A decision-analytic model was developed to estimate the cost-
effectiveness of fluticasone furoate vs. mometasone furoate. Patients initiated on
treatment either completed initial therapy or switched to second line therapy due
to non-response. Probability of a switch and resource use was based on expert
panel and literature. Costs were based on local drug acquisition costs, local cost
estimates for outpatient and hospitalization. Effectiveness was defined as the net
improvement in Total Ocular Symptom Score (TOSS) at 12 weeks from Keith PK.
2009 study. The analysis was carried out from the perspective of the Mexican
health care system and all costs are reported in 2010 US dollars. RESULTS: The
corresponding health effects were 0.47 net improvement TOSS for fluticaone fu-
roate and 0.31 for mometasone furoate regimen. The mean total cost of the fluti-
caone furoate regimenwas $ 627 compared with $ 827 for the furoatemometasone
regimen. Treatment with fluticasone furoate compared to treatment with mome-
tasone furoate was less costly and resulted in a greater net improvement of TOSS.
Probabilistic sensitivity analyses demonstrated that the cost savings observed
were maintained over a wide range of alternative values for costs and resource
utilization. CONCLUSIONS: Cost-effectiveness analysis indicated the dominance
of fluticasone furoate over mometasone furoate because of both lower costs and
greater efficacy. Cost savings with fluticasone furoate were attributable to lower
drug acquisition costs. In addition, a net improvement in ocular symptomsmay be
expected in allergic rhinitis patients.
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OBJECTIVES: In Central American countries, the economic burden of tobacco has
not been assessed. In Costa Rica, a study demonstrated that tobacco-related dis-
eases represent high costs for the health system. The aim of this study was to
assess the cost-effectiveness of varenicline compared to other existing strategies
for smoking cessation within a 20-year time horizon in an adult population cohort
from Central American and the Caribbean countries using the healthcare payer’s
perspective.METHODS: The Benefits of Smoking Cessation on Outcomes (BENESCO)
simulationmodelwas used for an adult cohort in Costa Rica, Panama, Nicaragua, El
Salvador and Dominican Republic (n  19,429,581). Smoking cessation therapies
compared were varenicline (0.5–2 mg/day) versus bupropion (300 mg/day); NRT
(5-10 mg/day) and unaided cessation. Effectiveness measures were: Life-Year
gained (LYG) and quality-adjusted life-year gained (QALY’s). Resource use and
costs data were obtained from country’s Ministry of Health and/or Social Security
Institutions (2008-2009). The model used a 3% discount rate for costs (expressed in
2009 US dollars) and health outcomes. Probabilistic sensitivity analyses (PSA) were
conducted and acceptability curves were constructed. RESULTS: Varenicline re-
duced smoking-related morbidity, mortality and healthcare costs. Mortality in the
varenicline arm was reduced by 5,738, 7,425 and 14,007 deaths compared with
bupropion, NRT and unaided cessation. The net average cost per additional quitter
showed that varenicline was cost-saving against competing alternatives. The cost
per additional quitter on varenicline was US$-269 compared with bupropion and
US$2,624 compared with unaided cessation. Cost-effectiveness analyses showed
that varenicline was the dominant strategy. At a willingness-to-pay of US$10,000/
QALY, the probability that varenicline is cost-effective met 100%. PSA results sup-
port the robustness of the findings.CONCLUSIONS: Smoking cessation therapywith
varenicline is cost-saving for Central American countries. These results could help to
reduce the tobacco related disease burden and align cost-containment policies.
PRS17
COST EFFECTIVENESS OF TOP 20 HIGHEST SELLING DRUGS
Aggarwal S
PAREXEL Consulting, Bethesda, MD, USA
OBJECTIVES: The recently made coverage decisions by UK’s NICE, Scotland’s SMC
and the allocation of $1.1Billion for comparative effectiveness research by the
United States, are strong indicators of trends in pricing and reimbursement that
are likely to be observed in the future. To gain an additional insight into these
trends,we analyzed the cost effectiveness studies for the top twenty highest selling
drugs ($80-95B worldwide sales). METHODS: The Top 20 drugs were selected
based on their worldwide sales. For this analysis, we segmented these drugs into
categories as primary care, specialty, small molecules, biologics, therapy areas and
availability of generic alternatives. We analyzed the cost effectiveness studies that
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